In an attempt to define biochemical and clinical changes that occur when patients with rheumatoid arthritis are exposed for the first time to 'specific antirheumatoid' therapy, and to see if these changes differ between drugs we have performed serial biochemical and clinical assessments over the first 6 months of treatment with a series of drugs for which antirheumatoid action has been claimed. Our results for groups of 15 patients treated with Dpenicillamine' 2 and alclofenac2 have been described. We have now added 2 Alkaline phosphatase
GGTP=gamma glutamyl transpeptidase.
group (Fig. 1) and the acute-phase proteins, ESR, plasma viscosity, serum sulphydryl, serum histidine, globulin, and total protein (Fig. 2) . In addition a statistically significant reduction in mean white cell count from baseline values was observed, though in no individual did this necessitate any change in therapeutic regimen. Five patients showed a steady fall in platelet count, also-within the normal range, though there was no significant reduction in mean data.
STATISTICAL ASSESSMENTS
Correlation matrices for both HCQ and gold therapy are shown in Table IA and B respectively. In each matrix the biochemical variables are shown in ranking order, those at the top correlating better with the clinical variables than those at the bottom for that particular drug. Significant correlations were demonstrated between a large number of clinical and laboratory variables as denoted by p levels of less than 005. This was particularly noticeable in the gold-treated group, where correlations were in general stronger and more numerous.
The 2 treatment groups were seen to be well matched at week 0 (Table 2) , with only globulin showing a significant difference.
Discussion
The use of serum biochemical changes in defining antirheumatoid drug efficacy has been previpusly established.' I In terms of the acute-phase proteins, ESR, and plasma viscosity, HCQ produced a later (as defined by the time of significant change in serum biochemistry) and less marked change than did gold or D-penicillamine.2 This suggests that HCQ, despite its confirmed efficacy in controlled studies in the treatment of RA,89 is nevertheless less effective than the more established antirheumatoid drugs. The particular value of plasma viscosity in the management of patients receiving hydroxychloroquine is discussed elsewhere. 10 This finding is substantiated in terms of the correlation matrices constructed between clinical and biochemical variables. Correlations, were fewer and weaker for HCQ than for both gold and D-penicillamine.1 Each matrix was constructed from 144 Pearson correlations each based on 8 data pairs. Hence one can expect 7 falsely significant correlations at p<0 05 (1 in 20) to arise by chance. There were in fact 19 correlations of p<005 in the HCQ matrix and 24 in the gold matrix, so about one-third of all Biochemical indices ofresponse to hydroxychloroquine andsodium aurothiomalate in rheumaloidarthritis 487 these correlations at p <005 were falsely significant. However, this does not detract from our overall finding that the greater improvement in the biochemical and clinical variables for gold-treated patients gave rise to a larger number of significant correlations.
While the acute-phase proteins, ESR, and plasma viscosity10 have been shown to be non-specific indices of disease improvement, some biochemical variables showed changes which were more specific. For example, serum histidine failed to improve with HCQ therapy1' but, in contrast to a previous report,'2 showed an upward trend with gold therapy. Haemoglobin levels rose towards normal with gold and D-penicillaminel but, in agreement with previous work9 and in contrast to others,8 remained unchanged with HCQ. The total serum sulphydryl level improved for gold and D-penicillamine.13
While this could be attributed to the sulphydryl groups that form part of the structure of these two drugs, we favour an indirect change consequent upon the therapeutic action of these drugs or a combination of both of these as the reason for increased total serum sulphydryl. HCQ's failure to increase serum sulphydryl levels may reflect the drug's weaker activity rather than the lack of sulphydryl group in its structure.
In this parallel group study the analysis showed that week 0 data were essentially matched between the 2 groups, and hence differences in the response of serum histidine, haemoglobin, and serum sulphydryl levels following HCQ therapy compared with gold would suggest a different mode of action of this drug. The failure of total serum sulphydryl, haemoglobin, and histidine levels to improve with HCQ therapy is reflected by the lack of significant correlation between these measurements and the clinical variables.
For the gold-treated patients a temporary rise in the acute-phase reactants was observed at week 2 with the exception of C-reactive protein. Inequality of patient groups must also be considered in a nonrandomised study. All patients conformed to identical admission criteria and were drawn from the same patient pool, the study being completed within 1 year. We think it unlikely the nature of rheumatoid disease would alter in this short period, and the failure to show a significant difference between patient groups on entry makes a seasonal bias unlikely. Assay of biochemical standards at regular intervals excluded anomalies due to laboratory reagents or technique, and variation in clinical assessment, perhaps the greatest potential source of error, was minimised by intermittent tests of interobserver error between the 2 participating metrologists.
Our findings in this human test system, akin to the testing of drugs at an early stage of their development in an animal model, suggest that HCQ occupies an intermediate position between the more effective drugs, such as gold and D-penicillamine,2 and weaker drugs, such as alclofenac2 and aspirin.14 Controlled clinical trials confirm this ranking order of effectiveness, lending credence to our human test system as a method for detecting antirheumatoid activity in novel compounds. 
